A gluten-free grain concentrate (GFGC) drug product and stepwise process to prepare GFGC from the treatment of raw unground wheat germ, is provided resulting in a product having at least three active components including (a) 1% to 3% 2,6-dimethoxy-1,4-hydroquinone； (b) 2% to 4% monomethoxy-1,4-benzoquinone； and (c) 0.5% to 1.5% monomethoxy-1,4-hydroquinone； and at least one inactive component: 2,6 dimethyl benzoquinone.
